GSK3β-IN-3 

GSK3β-IN-3 is an ATP-competitive GSK-3β inhibitor (IC₅₀ = 0.90 μM). GSK3β-IN-3 can reduce the phosphorylation level of tau protein in the BR5706 strain and reduce the deposition of Aβ aggregates in the CL2006 strain, and can be used to research Alzheimer's disease (AD)^[1].

GSK3β-IN-3 (Compound 66) (0.01-100 μM) inhibits GSK-3β with IC₅₀ of 0.90 μM^[1].

GSK3β-IN-3 (0-50 μM) shows ATP-competitive inhibition of the GSK-3β enzyme^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GSK3β-IN-3 (Compound 66) (10 μM) reduces p-Tau (Ser396) levels in the BR5706 strain in C. elegans^[1].

GSK3β-IN-3 (10 μM) increases quantity of thrashes, reduces Aβ deposition in the CL2006 C. elegans strain^[1].

GSK3β-IN-3 shows good stability in human microsomes^[1].

GSK3β-IN-3 has the potential to cross the BBB in PAMPA-BBB test^[1].

GSK3β-IN-3 has high plasma protein binding, shows plasma protein binding 96.4%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

310.80

C₁₄H₁₅ClN₂O₂S

301359-45-5

CCOC(C1=C(NC(NC1C2=CC=CC=C2Cl)=S)C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sukanya S, et al. Exploring 2-Thioxo-1,2,3,4-tetrahydropyrimidines as Dual Acting GSK-3β/Aβ Aggregation Inhibitors: Implications for Alzheimer's Disease Treatment. Drug Dev Res. 2025 Jun;86(4):e70112.  [Content Brief]